A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract
Francisco M. Marty, Roy F. Chemaly, Kathleen M. Mullane, Dong Gun Lee, Hans H. Hirsch, Catherine B. Small, Anne Bergeron, Shmuel Shoham, Per Ljungman, Alpana Waghmare, Elodie Blanchard, Yae Jean Kim, Matt McKevitt, Danielle P. Porter, Robert Jordan, Ying Guo, Polina German, Michael Boeckh, Timothy R. Watkins, Jason W. ChienSanjeet S. Dadwal
Dive into the research topics of 'A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract'. Together they form a unique fingerprint.